GSK vs UPC

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Jul 04, 2026

GSK

66.2
AI Score
VS
GSK Wins

UPC

57.9
AI Score

Investment Advisor Scores

GSK

Jul 04, 2026
66score
Recommendation
BUY

UPC

Jul 04, 2026
58score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric GSK UPC Winner
Forward P/E 21.5054 0 Tie
PEG Ratio 19.3637 0 Tie
Revenue Growth 1.5% -14.1% GSK
Earnings Growth 8.4% -82.0% GSK
Tradestie Score 66.2/100 57.9/100 GSK
Profit Margin 17.8% -20.6% GSK
Beta 1.00 1.00 Tie
Implied Volatility N/A N/A Tie
AI Recommendation BUY HOLD GSK

Frequently Asked Questions

Based on our detailed analysis, GSK is currently the stronger investment candidate, winning 5 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.